Protocol Number: 99-H-0056

Title:

Pulmonary Fibrosis with Rheumatoid Arthritis: Definition of the Natural History of Disease

Number:

99-H-0056

Summary:

Pulmonary fibrosis (PF) is a condition in which the lungs of a patient become scarred and fibrous. It has been known to occur in as many as 40% of patients diagnosed with rheumatoid arthritis (RA). The cause of the pulmonary fibrosis in patients with RA is unknown.

Patients participating in this study will undergo a series of tests and examinations before and throughout the study. The tests include blood and urine tests, electrical measures of heart function (ECG), chest x-rays, CAT scans, nuclear medicine scans, breathing tests, exercise tests, and fiberoptic bronchoscopy.

The goals of this study are to:

1. Estimate how common pulmonary fibrosis is in patients with rheumatoid arthritis,

2. Describe the natural course of pulmonary fibrosis in patients with rheumatoid arthritis,

3. Estimate the survival rate of patients with pulmonary fibrosis and rheumatoid arthritis, and

4. Learn more about the factors that contribute to the development or progression fibrotic lung disease.

Sponsoring Institute:

National Heart, Lung and Blood Institute (NHLBI)

Recruitment Detail

Type: Active Accrual Of New Subjects

Gender: Male & Female

Referral Letter Required: Yes

Population Exclusion(s): Children

Eligibility Criteria:

Non-smokers (never smoked or no smoking within the previous 2 years) who are 21 years of age or older with any of the following:

Rheumatoid arthritis with biopsy-proven pulmonary fibrosis or;

Rheumatoid arthritis only, or;

Biopsy-proven idiopathic pulmonary fibrosis.

Must not have forced expiratory volume in one second (FEV1) less than 1L.

Must not have inhalational exposure to fibrogenic fibers or dusts (e.g., asbestos, silica, coal, beryllium).

Must not have chronic cardiopulmonary disorders other than pulmonary fibrosis.

Must not have other collagen vascular disorders (e.g., systemic lupus erythematosus, scleroderma, polymyositis, mixed connective tissue disease).

Must not have non-rheumatoid arthritis.

Must not have viral infections associated with pulmonary fibrosis (e.g., hepatitis B, hepatitis C, human immunodeficiency virus).

Must not have uncorrectable bleeding diathesis.

Must not be pregnant or lactating.

Special Instructions: Currently Not Provided

Keywords:

Interstitial Lung Disease

Collagen Vascular Disease

Extracellular Matrix

Pulmonary Function

DTPA Lung Clearance Scan

Recruitment Keywords:

Rheumatoid Arthritis

Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Conditions:

Pulmonary Fibrosis

Rheumatoid Arthritis

Investigational Drug(s):

None

Investigational Device(s):

None

Contacts:

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citations:

Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy

Pulmonary involvement in rheumatoid arthritis

Rheumatoid arthritis lung disease Determinants of radiographic and physiologic abnormalities

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Networks and Applications, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

Warren Grant Magnuson Clinical Center (CC)
National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/20/2004